(BIM) Biomerieux - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: PA (France) | Market Cap: 11.046m EUR | Total Return: -18.8% in 12m
Diagnostic Tests, Culture Media, Monitoring Systems, Data Software
Total Rating 52
Safety 90
Buy Signal -0.91
Diagnostics & Research
Industry Rotation: +0.8
Industry Rotation: +0.8
Market Cap:
12.9B
Avg Turnover: 11.0M EUR
Avg Turnover: 11.0M EUR
ATR:
2.22%
Peers RS (IBD): 7.2
Peers RS (IBD): 7.2
Risk 5d forecast
Volatility26.1%
Rel. Tail Risk-6.01%
Reward TTM
Sharpe Ratio-1.26
Alpha-24.53
Character TTM
Beta0.079
Beta Downside-0.041
Drawdowns 3y
Max DD30.55%
CAGR/Max DD-0.06
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: BIM Biomerieux
bioMérieux S.A. (BIM) is a French in vitro diagnostics company specializing in infectious diseases. It operates globally across clinical and industrial applications.
The companys product portfolio includes a wide range of diagnostic solutions. Key offerings include chromogen culture media (CHROMID RANGE), blood culture systems (BACT/ALERT VIRTUO), and polymerase chain reaction (PCR) systems (BIOFIRE, BIOFIRE SPOTFIRE). PCR is a fundamental technology in molecular diagnostics, enabling rapid and accurate detection of pathogens.
BIM also provides mass spectrometry (VITEK MS) and automated identification and antimicrobial susceptibility testing (VITEK 2) systems. Antimicrobial susceptibility testing is crucial for guiding appropriate antibiotic treatment and combating antimicrobial resistance, a significant global health challenge.
Additional products include DNA/RNA extraction reagents (EMAG, NUCLISENS), solutions for food industry microorganism detection (GENE-UP, VERIFLOW), and various microbiology instruments (CHEMUNEX, TEMPO). The company also offers software for diagnostic support (Biomérieux vision suite) and laboratory consultancy services.
For more in-depth data and analysis, consider exploring ValueRays comprehensive research tools.
- Infectious disease diagnostics demand drives clinical segment revenue
- Industrial microbiology solutions sustain growth in food safety
- Regulatory approvals for new diagnostic platforms impact market access
- Competition in PCR and mass spectrometry segments pressures pricing
- Global health crises increase demand for rapid diagnostic testing
Piotroski VR‑10 (Strict)
8.5
| Net Income: 681.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 10.11 > 1.0 |
| NWC/Revenue: 21.29% < 20% (prev 21.73%; Δ -0.44% < -1%) |
| CFO/TA 0.26 > 3% & CFO 1.46b > Net Income 681.4m |
| Net Debt (-108.4m) to EBITDA (1.60b): -0.07 < 3 |
| Current Ratio: 2.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (119.0m) vs 12m ago 0.33% < -2% |
| Gross Margin: 53.06% > 18% (prev 0.53%; Δ 5.25k% > 0.5%) |
| Asset Turnover: 127.3% > 50% (prev 104.8%; Δ 22.44% > 0%) |
| Interest Coverage Ratio: 41.54 > 6 (EBITDA TTM 1.60b / Interest Expense TTM 22.6m) |
Altman Z''
3.42
| A: 0.26 (Total Current Assets 2.54b - Total Current Liabilities 1.06b) / Total Assets 5.57b |
| B: 0.07 (Retained Earnings 397.5m / Total Assets 5.57b) |
| C: 0.17 (EBIT TTM 940.9m / Avg Total Assets 5.45b) |
| D: 0.28 (Book Value of Equity 409.5m / Total Liabilities 1.47b) |
| Altman-Z'' Score: 3.42 = A |
Beneish M
-3.16
| DSRI: 0.92 (Receivables 1.01b/888.6m, Revenue 6.93b/5.58b) |
| GMI: 0.99 (GM 53.06% / 52.57%) |
| AQI: 0.86 (AQ_t 0.25 / AQ_t-1 0.29) |
| SGI: 1.24 (Revenue 6.93b / 5.58b) |
| TATA: -0.14 (NI 681.4m - CFO 1.46b) / TA 5.57b) |
| Beneish M-Score: -3.16 (Cap -4..+1) = AA |
What is the price of BIM shares?
As of April 10, 2026, the stock is trading at EUR 89.55 with a total of 118,443 shares traded.
Over the past week, the price has changed by -4.38%, over one month by -6.13%, over three months by -20.68% and over the past year by -18.80%.
Over the past week, the price has changed by -4.38%, over one month by -6.13%, over three months by -20.68% and over the past year by -18.80%.
Is BIM a buy, sell or hold?
Biomerieux has no consensus analysts rating.
What are the forecasts/targets for the BIM price?
| Analysts Target Price | - | - |
Biomerieux (BIM) - Fundamental Data Overview
as of 05 April 2026
Market Cap USD = 12.88b (11.05b EUR * 1.1659 EUR.USD)P/E Trailing = 28.0389
P/E Forward = 19.9203
P/S = 2.7142
P/B = 2.6655
P/EG = 1.338
Revenue TTM = 6.93b EUR
EBIT TTM = 940.9m EUR
EBITDA TTM = 1.60b EUR
Long Term Debt = 211.3m EUR (from longTermDebt, last quarter)
Short Term Debt = 131.4m EUR (from shortTermDebt, last quarter)
Debt = 461.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -108.4m EUR (from netDebt column, last quarter)
Enterprise Value = 10.94b EUR (11.05b + Debt 461.4m - CCE 569.8m)
Interest Coverage Ratio = 41.54 (Ebit TTM 940.9m / Interest Expense TTM 22.6m)
EV/FCF = 14.12x (Enterprise Value 10.94b / FCF TTM 774.5m)
FCF Yield = 7.08% (FCF TTM 774.5m / Enterprise Value 10.94b)
FCF Margin = 11.17% (FCF TTM 774.5m / Revenue TTM 6.93b)
Net Margin = 9.83% (Net Income TTM 681.4m / Revenue TTM 6.93b)
Gross Margin = 53.06% ((Revenue TTM 6.93b - Cost of Revenue TTM 3.25b) / Revenue TTM)
Gross Margin QoQ = 49.00% (prev 57.09%)
Tobins Q-Ratio = 1.96 (Enterprise Value 10.94b / Total Assets 5.57b)
Interest Expense / Debt = 1.63% (Interest Expense 7.50m / Debt 461.4m)
Taxrate = 24.39% (76.2m / 312.4m)
NOPAT = 711.4m (EBIT 940.9m * (1 - 24.39%))
Current Ratio = 2.39 (Total Current Assets 2.54b / Total Current Liabilities 1.06b)
Debt / Equity = 0.11 (Debt 461.4m / totalStockholderEquity, last quarter 4.10b)
Debt / EBITDA = -0.07 (Net Debt -108.4m / EBITDA 1.60b)
Debt / FCF = -0.14 (Net Debt -108.4m / FCF TTM 774.5m)
Total Stockholder Equity = 4.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.51% (Net Income 681.4m / Total Assets 5.57b)
RoE = 16.92% (Net Income TTM 681.4m / Total Stockholder Equity 4.03b)
RoCE = 22.20% (EBIT 940.9m / Capital Employed (Equity 4.03b + L.T.Debt 211.3m))
RoIC = 16.94% (NOPAT 711.4m / Invested Capital 4.20b)
WACC = 6.06% (E(11.05b)/V(11.51b) * Re(6.26%) + D(461.4m)/V(11.51b) * Rd(1.63%) * (1-Tc(0.24)))
Discount Rate = 6.26% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 33.33 | Cagr: 0.01%
[DCF] Terminal Value 88.23% ; FCFF base≈545.2m ; Y1≈672.6m ; Y5≈1.15b
[DCF] Fair Price = 277.7 (EV 32.64b - Net Debt -108.4m = Equity 32.75b / Shares 118.0m; r=6.06% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -9.53 | EPS CAGR: -47.24% | SUE: 0.0 | # QB: 0
Revenue Correlation: 22.56 | Revenue CAGR: 8.77% | SUE: -0.04 | # QB: 0
EPS current Year (2026-12-31): EPS=4.74 | Chg7d=+0.002 | Chg30d=-0.011 | Revisions Net=-8 | Growth EPS=+2.1% | Growth Revenue=+4.7%
EPS next Year (2027-12-31): EPS=5.35 | Chg7d=+0.004 | Chg30d=-0.015 | Revisions Net=-7 | Growth EPS=+13.0% | Growth Revenue=+7.2%
[Analyst] Revisions Ratio: -0.80 (1 Up / 9 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 4.4% (Discount Rate 7.9% - Earnings Yield 3.6%)
[Growth] Growth Spread = +2.9% (Analyst 7.2% - Implied 4.4%)